CHONGQING PHARSCIN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.06 CNY | -3.40% |
|
-4.74% | -15.47% |
| Apr. 10 | Chongqing Pharscin Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023 | CI |
| Apr. 03 | Pharscin Pharma Gets License to Produce Olmesartan Medoxomil Amlodipine Tablets | MT |
| Sales 2021 | 846M 117M | Sales 2022 | 785M 109M | Capitalization | 8.5B 1.17B |
|---|---|---|---|---|---|
| Net income 2021 | 91M 12.58M | Net income 2022 | 98M 13.54M | EV / Sales 2021 | 8.26 x |
| Net cash position 2021 | 259M 35.85M | Net cash position 2022 | 503M 69.56M | EV / Sales 2022 | 10.2 x |
| P/E ratio 2021 |
78.9
x | P/E ratio 2022 |
83.4
x | Employees | 1,416 |
| Yield 2021 |
0.28% | Yield 2022 |
0.34% | Free-Float | 18.33% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.40% | ||
| 1 week | -4.74% | ||
| Current month | -6.85% | ||
| 1 month | -11.52% | ||
| 3 months | -18.83% | ||
| 6 months | -31.08% | ||
| Current year | -15.47% |
1 week
12.80
14.51
1 month
12.8015.63
Current year
9.8217.43
1 year
9.8220.50
3 years
9.8234.85
5 years
9.8234.85
10 years
5.9847.92
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Ying Liu
CEO | Chief Executive Officer | 61 | 15-08-18 |
Kai Yu Xu
CHM | Chairman | 58 | 00-09-30 |
Xiao Yan Peng
DFI | Director of Finance/CFO | 50 | 02-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jia Ming Li
BRD | Director/Board Member | 58 | 22-05-17 |
Hong Tao You
CHM | Chairman | 61 | 15-08-18 |
Xiao Ying Liu
CEO | Chief Executive Officer | 61 | 15-08-18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-15 | 13.06 | -3.40% | 2,765,754 |
| 24-04-12 | 13.52 | -0.88% | 1,923,700 |
| 24-04-11 | 13.64 | -1.73% | 2,722,500 |
| 24-04-10 | 13.88 | -3.07% | 3,673,641 |
| 24-04-09 | 14.32 | +4.45% | 3,928,523 |
End-of-day quote Shenzhen S.E., April 14, 2024
More quotes
Chongqing Pharscin Pharmaceutical Co Ltd is a China-based company principally engaged in the research, development, production and sale of Chinese patent drugs and chemical drugs. The Company operates three segments: Pharmaceutical Industry segment, Commercial Circulation segment and Retail segment. The Company's products are categorized into the pharmaceuticals of digestive system, nervous system, otorhinolaryngology, cardiovascular and cerebrovascular systems and immune systems. The Company's products include Weidimei (aluminum carbonate tablets), Ganju Bingmei Tablets, Bawei Qilong Particles, Liuwei Anshen Capsules, Sodium Ferulate for Injection, Omeprazole Sodium for Injection and Gabexate Mesilate for Injection. The Company mainly distributes its products in domestic market.
Sector
Pharmaceuticals
Calendar
2024-04-28
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -15.47% | 753M | |
| +22.08% | 44.25B | |
| +19.80% | 22.33B | |
| +10.34% | 13.36B | |
| +3.22% | 13.24B | |
| +37.09% | 11.27B | |
| -6.38% | 7.15B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.00% | 5.24B |
- Stock Market
- Equities
- 002907 Stock
